Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH

被引：9
|
作者：
Weitz, Ilene Ceil [1 ]
机构：
[1] Keck USC Sch Med, Jane Anne Nohl Div Hematol, Los Angeles, CA 90089 USA
来源：
JOURNAL OF BLOOD MEDICINE | 2023年 / 14卷
关键词：
PNH; complement inhibition; extravascular hemolysis; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; ECULIZUMAB; HEMOLYSIS;
D O I：
10.2147/JBM.S362220
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Pegcetacoplan is the newest inhibitor of the complement system to be approved by the FDA and EMA for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The cyclic peptide inhibitor of C3 was evaluated in several clinical trials in PHN leading to its approval. The focus of this paper will review the efficacy and safety of Pegcetacoplan (PEG), and considerations for use in patients with PNH.
引用
收藏
页码：239 / 245
页数：7
相关论文
共 50 条
  • [21] Incomplete Complement Inhibition In Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH) On Eculizumab-5 Year Experience From The National PNH Service Leeds
    Jones, Rachael
    Muus, Petra
    Munir, Talha
    Pike, Alexandra
    Arnold, Louise
    Gachev, Jeanifer
    Forrest, Briony
    Hillmen, Peter
    Griffin, Morag
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 201 - 202
  • [22] Real-World Treatment Outcomes of Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated with Pegcetacoplan and Complement Protein 5 Inhibitors (C5i)
    Majerus, Elaine M.
    Mulherin, Brian
    Wilson, Koo
    Fishman, Jesse
    Mellor, Jennifer
    Earl, Lucy
    Roeth, Alexander
    BLOOD, 2023, 142
  • [23] Three Years On: The Role of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH) since Its Initial Approval
    Horneff, Regina
    Czech, Barbara
    Yeh, Michael
    Surova, Elena
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (16)
  • [24] Effect of complement C3 inhibition with pegcetacoplan in an iPSC-derived ALS neuromuscular junction model of neuroinflammation
    Li, Yan
    Smith, Virginia
    Skinner, Sarah
    Robertson, Ashley
    Lenkiu, Leticia
    Cannon-Patron, Heather
    Martinez, Daisy
    Hanson, Hannah
    Hickman, James J.
    Eyerman, David
    NEUROLOGY, 2023, 100 (17)
  • [25] Pegcetacoplan for the Treatment of Pediatric Complement 3 Glomerulonephritis: A Case Report
    Guzman, German Lozano
    PEDIATRIC NEPHROLOGY, 2024, 39 (01) : S157 - S158
  • [26] Characterization of Erythrocytes in PNH: Can We Predict Response to Complement Inhibition Based on Different Erythrocyte Markers?
    Solomou, Elena E.
    Anastasiadi, Alkmini
    Papaioannou, Maria
    Angelopoulou, Maria
    Zikos, Panagiotis
    Assimakopoulos, Ioannis
    Dimou, Maria
    Tsaftaridis, Panagiotis
    Panse, Jens
    Tzounakas, Vasileios
    BLOOD, 2024, 144 : 1317 - 1318
  • [27] UNDERSTANDING THE REAL-WORLD CLINICAL EFFECTIVENESS OF PEGCETACOPLAN FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
    Fishman, J.
    Rich, C.
    Wilson, K.
    Mellor, J.
    Earl, L.
    Taylor, Y.
    Conyers, J.
    Simons, A.
    VALUE IN HEALTH, 2023, 26 (06) : S56 - S56
  • [28] Comparative effectiveness of pegcetacoplan (PEG) versus ravulizumab (RAV) and eculizumab (ECU) in complement inhibitornaive patients with paroxysmal nocturnal hemoglobinuria (PNH): A matching-adjusted indirect comparison
    Yee, Christopher
    Wong, Raymond
    Fishman, Jesse
    Wilson, Koo K.
    Al-Adhami, Mohammed
    Yeh, Michael
    Hakimi, Zalmai
    Zion, Abigail
    Huynh, Lynn
    Duh, Mei Sheng
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 380 - 380
  • [29] Understanding the Real-World Clinical Effectiveness of Pegcetacoplan for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Fishman, Jesse
    Rich, Carly
    Wilson, Koo
    Mellor-Bowman, Jennifer
    Earl, Lucy
    Taylor, Yasmin
    Simons, Alice
    Conyers, Joe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S369 - S370
  • [30] Therapeutic Complement Inhibition: New Developments
    Emlen, Woodruff
    Li, Wenhan
    Kirschfink, Michael
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2010, 36 (06): : 660 - 668
12345